Add in a $31 million market capitalization and potentially significant cash burn, and Ocugen stock self-evidently is not for risk-averse investors. Generally, financial analysts struggle with this sector because these equities rise and fall not on revenue or earnings, but the success of clinical trials. 2023 InvestorPlace Media, LLC. Keith Speights owns shares of Pfizer. The odds of Ocugen stock winding up at zero are material. Create your Watchlist to save your favorite quotes on Nasdaq.com. Will Be Even Bigger Than Your Wildest Expectation, 7 Over-$100 Stocks That Are Worth Every Penny, Louis Navellier and the InvestorPlace Research Staff, 5 Penny Cryptos With the Most Potential for Growth. The first is that Ocugen is facing potential delisting from the NASDAQ given that its share price still sits well below $1. But the allure of the space is that when a company wins, its shareholders win big. Objective investors could have clearly seen then that there actually were significant reasons to be concerned. OCGN | Ocugen Inc. Stock Price & News - WSJ Ocugen Inc. OCGN (U.S.: Nasdaq) REAL TIME 12:30 PM EST 02/21/23 $0.9819USD -0.0981 -9.08% Volume 3,761,699 65 Day Avg Vol 5,026,332 1 Day Range. It announced on Dec. 9 of last year 17 months later that it was 50% through enrollment. If they have solid financials, but their trials continually fail, they will likely not succeed. That pathway will likely require the company to conduct further clinical testing of the vaccine in the U.S. Are there any other near-term catalysts for the biotech stock? Probably the most important thing to do after Ocugen's crash, though, is to identify lessons learned and apply them to future investing decisions. There's still a chance that the vaccine could receive a green light in Canada. Plus500. It brings in no revenue. Ocugen had to go an unusual route to go public. This decision isn't surprising, considering that Ocugen previously abandoned the pursuit of an EUA path for the vaccine in adults. All rights reserved. Here are three prudent steps to take. The reverse merger with Histogenics was a disappointment, but the purchase price for the NeoCart intellectual property suggests that company had little chance of survival on its own. Keith Speights has no position in any of the stocks mentioned. It means that raising capital will be more difficult going forward. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. But there is no question some big-name stocks performed better than others along the way. Keith Speights has no position in any of the stocks mentioned. Axsome Therapeutics (NASDAQ:AXSM) had an equity value below $75 million in March 2017; its now worth over $3 billion after rising over 1,000% last year. Shares of Ocugen (OCGN 4.03%) were crashing 19.2% lower as of 11:23 a.m. The average Ocugen stock price for the last 52 weeks is 2.10. From a broader perspective, the risk is the same as it is across biotech: most candidates fail. How long might it take for Ocugen to win full FDA approval for Covaxin? Ocugen Inc. is a clinical stage biopharmaceutical company. Copy and paste multiple symbols separated by spaces. The statistics support having long-term exposure to this asset class. Buy These 2 Stocks in 2023 and Hold for the Next Decade, 2 Stocks That Are About to Make Their Shareholders Richer, Join Over Half a Million Premium Members And Get More In-Depth Stock Guidance and Research, Motley Fool Issues Rare All In Buy Alert, the company's fourth-quarter conference call last month, Copyright, Trademark and Patent Information. Long-term debt of $1.6 million is not a back-breaker either. Not an offer or recommendation by Stocktwits. Copyright quotes delayed at least 15 minutes, all others at least 20 minutes. Maybe it pans out for Ocugen and I wish the team (and its investors) the best of luck. Ocugen executives even sounded cautiously optimistic in the company's fourth-quarter conference call last month. The reverse merger that brought Ocugen to the public markets led to huge losses but some investors are buying the dip. Ocugen sold $25 million of stock in a private placement before the merger. Emergency Use Authorization (EUA) for Covaxin, the COVID-19 vaccine developed by Ocugen's partner, Bharat Biotech. The Ocugen deal is a way to salvage some limited value. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA. Stock Price Forecast The 6 analysts offering 12-month price forecasts for Ocugen Inc have a median target of 4.75, with a high estimate of 8.00 and a low estimate of 3.00. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. However, even from this limited vantage point, OCGN appears destined to fail. MALVERN, Pa., April 28, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Nasdaq: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness. Please check your download folder. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. 2023, Nasdaq, Inc. All Rights Reserved. Remember, though, that Moderna achieved this while working closely with the U.S. government (including receiving funding from Uncle Sam) and during a period when vaccines weren't widely available. For most of its history, what we now know as Ocugen stock was Histogenics, a cell therapy company focused on orthopedics. These symbols will be available throughout the site during your session. 1125 N. Charles St, Baltimore, MD 21201. An unprofitable biotech that focused on commercializing therapies to cure blindness prior to the present pandemic, Ocugen ( OCGN) stock took on a new life on December 22, when it announced. Our 3 Top Picks. From the outside looking inward, it looks like a marriage of two people who got together simply because nobody else would take them. Sie knnen Ihre Einstellungen jederzeit ndern, indem Sie auf unseren Websites und Apps auf den Link Datenschutz-Dashboard klicken. Ocugen abandoned its pursuit of a U.S. EUA for Covaxin in immunizing adults last year. Keith Speights for A bout of buying in late July sent shares from 20 cents apiece to above 90 cents a share a few days later. The simplest thing to do is to hang onto the stock and hope that it recovers sooner or later (which is a possibility). Healthy companies do not undergo 1-for-60 reverse stock splits like this one did in September 2019. Histogenics shareholders then received about 14% of the company, according to the merger prospectus. Assuming it wins approval for the vaccine, the challenge for the company then will be to achieve commercial success. ET by MarketWatch Automation Ocugen Inc. stock falls Tuesday, underperforms market Feb. 21, 2023 at 5:14. These options will be cheaper than owning the stock itself. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off. Literally, zero. A $30 million market capitalization doesnt mean Ocugen has no chance. This decision. In November, Bharat Biotech began Phase 3 testing of Covaxin in India. Names like Ocugen (NASDAQ:OCGN) arent trading for about 50 cents apiece by accident. The median estimate. Under the terms of the agreement, Ocugen is entitled to 45% of the profits from the commercialization of Covaxin in the U.S. and Canada. Nor should one look forward to OCGN stock to becoming the next GW Pharmaceuticals (NASDAQ:GWPH) or Cara Therapeutics (NASDAQ:CARA). How can we possibly evaluate a stock on a fundamental basis with that being reality? Matthew McCall left Wall Street toactually helpinvestors by getting them into the worlds biggest, most revolutionary trends BEFORE anyone else. Ocugen Chairman and CEO Shankar Musunuri Ocugen The company's stock opened at $8.24 per share Tuesday, up 96 cents. Don't overlook another approach, especially if you're still sitting on a nice gain even after last week's major sell-off. Those reverse splits generally are poorly received by the market, even if in theory they should have little to no practical impact on trading. Our 3 Top Picks. quotes delayed at least 15 minutes, all others at least 20 minutes. Until July 20, when OCGN stock jumped about 20%, shares were down 21% from the March low. CanSinoBio is a legitimate player in the industry; the companys market cap is near $2 billion after a nice rally in recent weeks. 10 stocks we like better than Ocugen, Inc.When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. I will concede this: The one great thing about the stock market is there is a style for everyone. However, sometimes the optimism isn't justified. The generic form of brimonidine, the active ingredient, is not approved for the condition, according to Ocugens most recent presentation. Covaxin doesn't have an advantage in terms of dosing compared to these leading vaccines. Just a few days ago, Ocugen (NASDAQ: OCGN) was flying high with shares up more than 460% year to date. Shares fell 72% on the news, and kept falling after Histogenics decided to suspend development of the product in December 2018. That's not going to happen now. 5 Hypergrowth Stocks With 10X Potential in 2023, Robert Bollinger: Meet the Man Behind Mullens Push Into Commercial EVs, A.I. As with many biotech stocks, the most likely outcome is for the company to fail, and for shareholders to wind up with zero. Weve now already seen a 50% correction in the stock price, with shares changing hands around 46 cents per share. Shares declined 85% in three sessions around the closing of the merger, which also included a 1-for-60 reverse stock split. Biotechnology stocks like Ocugen (NASDAQ:OCGN) are among the markets riskiest plays. Ocugen has responded to Health Canada regarding deficiencies identified with its regulatory filing for Covaxin. You canfollow Will on Twitterat @HealyWriting. See disclosure here. COVID-19 vaccines from Pfizer and Moderna are already on the market in the U.S. with efficacy levels of 94% or greater. With $3.2 million in cash vs. current liabilities of $3.3 million, Ocugen likely has enough cash on hand to cover its short-term obligations. If were playing that game then Im buying LEAP call options on Apple and Amazon in March. OCGN does not even appear to have an apparent reason to exist. David and Tom just revealed what they believe are the ten best stocks for investors to buy right now and Ocugen, Inc. wasn't one of them! Lorem ipsum dolor sit amet, consectetur adipiscing elit. Over the next few weeks, Ocugen is expected to meet with the FDA to discuss how to advance COVAXINs development. If they invent a miracle treatment for a condition, the money will find its way to the stock. According to the prospectus, the combined company posted an operating loss of roughly $30 million in 2018. Another alternative is to sell some or all of your Ocugen stock and invest the money elsewhere. Moreover, Histogenics existed to treat orthopedic conditions, while Ocugen focused on rare eye diseases. Why Everyone Is Investing in 5G All WRONG, Americas #1 Stock Picker Reveals His Next 1,000% Winner, Revolutionary Tech Behind 5G Rollout Is Being Pioneered By This 1 Company, Radical New Battery Could Dismantle Oil Markets. By the beginning of March, the stock was still trading at 45 cents as news of the coronavirus spreading in China prompted concerns about a U.S. pandemic. Ocugen does have at least 180 days to cure that problem, but the simplest answer is for the company to execute a reverse stock split. The OCGN stock forecast 2022 outlook suggests that Ocugen's stock may struggle in the short term. ET on Friday. The huge gain came after the company's partner, Bharat Biotech, received emergency use authorization (EUA) in India for COVID-19 vaccine Covaxin. The point is, the risk/reward of owning something like Ocugen is simply not worth it vs. having even basic equity exposure. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*. 7 Travel Stocks to Buy Banking On Pent-Up Demand. The post There Are So Many Stocks to Buy Ocugen Isnt One of Them appeared first on InvestorPlace. However, an EUA in India doesn't mean that Covaxin is a slam dunk to win EUA in the U.S., as well. Those lessons will vary between different investors, but I'll point out a major one to keep in mind. Ocugen shares jumped to $3.50 on massive volume in December when the Covaxin partnership was announced. Do not expect a recovery in Ocugen stock. For investors new to the story, there are some positives when it comes to OCGN stock. Ocugens Big Run: One company that has been a home-run investment in the last year has been biotech stock Ocugen Inc (NASDAQ:OCGN). One thing seems certain, however:Ocugens fate as an investment is closely tied to the ultimate outcome of Covaxin. Financial Market Data powered by FinancialContent Services, Inc. All rights reserved. 1125 N. Charles St, Baltimore, MD 21201. In other words, it means that even by biotech standards OCGN stock is an enormously risky play. Copyright 2023 InvestorPlace Media, LLC. Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Considering the conditions facing the company, I do not recommend Ocugen stock regardless of risk tolerances. Just a few days ago, Ocugen (NASDAQ: OCGN) was flying high with shares up more than 460% year to date. When the symbol you want to add appears, add it to My Quotes by selecting it and pressing Enter/Return. That doesnt mean success is guaranteed. But realizing value in practice usually is a difficult endeavor. All rights reserved. Youre reading a free article with opinions that may differ from The Motley Fools Premium Investing Services. The short answer is: everything. Ocugen came to the market via what was essentially a reverse merger with Histogenics Corporation, a deal that closed at the end of September. The risk-reward proposition for Ocugen is obviously much different now than it was when individuals were buying the stock over the last several months. However, the marriage of Histogenics and Ocugen looks destined to end in a suicide pact instead of a mere divorce. Investors who have owned stocks in the last year have generally experienced some big gains. Create your Watchlist to save your favorite quotes on Nasdaq.com. With this, the newly formed Ocugen initiated a 60:1 reverse stock split. Klicken Sie auf Alle ablehnen, wenn Sie nicht mchten, dass wir und unsere Partner Cookies und personenbezogene Daten fr diese zustzlichen Zwecke verwenden. The broad point here is that, even with a ~$30 million market capitalization (based on updated share count information disclosed in an 8-K filing on Dec. 9), this is a company with a legitimate opportunity. But if they do, Ocugen stock at the least looks like an intriguing bet. The chances of anything more are small but the rewards could be huge. The agreement stipulates Ocugen will hold the vaccines U.S. rights, and the remaining details are expected to be finalized over the coming weeks. Almost all the headlines about Ocugen in the past year have been about the companys COVID-19 vaccine candidate. Type a symbol or company name. CanSinoBio will be able to fund much of the development of OCU300, Ocugens flagship product that targets oGVHD (ocular graft versus host disease), a common complication of bone marrow transplants. When the market crashed during the U.S. pandemic outbreak in March, shares of vaccine makers understandably soared as work began on developing vaccines to fight COVID-19. Some were undoubtedly anticipating a relatively quick EUA win for Covaxin followed by strong U.S. sales for the COVID-19 vaccine. Histogenics itself highlights the risks involved in small-cap biotech. Today, the stock has a $1.6 billion market cap despite just $42,620 in 2020 revenue. I will just say this on Ocugen: Theres a reason it trades for sub-$1 after hitting resistance near $180 in 2018. Unfortunately, both the merger and the reverse split have failed to stem the decline of former Histogenics stock. Lorem ipsum dolor sit amet, consectetur adipiscing elit. The FDA gave a thumbs-down to Ocugen's EUA request for the pediatric use of Covaxin. As of this writing, Vince Martin has no positions in any securities mentioned. But just because a company does not have crippling debt doesnt mean its a buy. CFO Sanjay Subramanian said that there was "the potential for near-term revenue," depending on the EUA. Bei der Nutzung unserer Websites und Apps verwenden wir, unsere Websites und Apps fr Sie bereitzustellen, Nutzer zu authentifizieren, Sicherheitsmanahmen anzuwenden und Spam und Missbrauch zu verhindern, und, Ihre Nutzung unserer Websites und Apps zu messen, personalisierte Werbung und Inhalte auf der Grundlage von Interessenprofilen anzuzeigen, die Effektivitt von personalisierten Anzeigen und Inhalten zu messen, sowie, unsere Produkte und Dienstleistungen zu entwickeln und zu verbessern. Even at around 40 cents per share, I would consider Ocugen stock overvalued. Still, Ocugen investors who bought one year ago and held on have generated a huge return on their investment. And its at least possible that OCGN could wind up being a winner. Written by Guys, theres no revenue here! This is most likely a result of the stocks meteoric rise and analysts inability to turnaround new price targets so quickly. The potential synergies of such a union do not seem clear. Its all about choice. There's no way, however, to know what the COVID-19 vaccine market dynamics will be two years from now. In the late summer of 2018, the stock crashed below $1 per share as investors sold off following a failed phase three trial. Sign up below to get this incredible offer! Even before that point, the most promising candidates generally can find funding. When the symbol you want to add appears, add it to Watchlist by selecting it and pressing Enter/Return. Disclaimer: The opinions expressed in this article are solely those of the featured analysts. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*. MALVERN, Pa., May 29, 2018 /PRNewswire/ -- Ocugen, Inc., a rapidly growing ophthalmology company developing a rich clinical pipeline of innovative therapies that address rare and underserved ocular diseases, today announced that it will present at the 2018 BIO International Convention, taking place June 4-7, 2018, in Boston. Instead, this appears destined to join the long list of failed biotech startups. It means that institutional investors focused on the sector largely have passed on the pipeline. Investors were hopeful that the small drugmaker would be able to win U.S. Investing is always a game of balancing risk and reward. The all-time high Ocugen stock closing price was, The average Ocugen stock price for the last 52 weeks is. Please check your download folder. The second is that the balance sheet still needs some help. Since its merger, Ocugen stock has continued the decline that occurred under the company that it took over, Histogenics. 2023 InvestorPlace Media, LLC. Pricing likely would be favorable, given the lack of alternative treatments. The Motley Fool has a disclosure policy. Cost basis and return based on previous market day close. More importantly, the 5-star analyst added, COVAXIN also induces comparable levels of neutralizing antibodies to those in human convalescent serum," which, the analyst believes," bodes well for the success of the ongoing Phase 3 trial in India.. But theres a big difference in having an edge flipping sub-$5 stocks vs. combing over this group as an investor looking for sound fundamentals and a mistakenly low stock price. 1125 N. Charles St, Baltimore, MD 21201. What Is the Best EV Stock to Buy Now? Today, the stock has a $1.6 billion market cap despite just $42,620 in 2020 revenue. However, when that occurred, Ocugen stock lost most of its value. While anything is possible, I would not anticipate a miracle here. Ocugen Inc Stock - OCGN Share Price Today, News and Discussion 0.90% SPY 0.59% QQQ 0.60% TSLA 6.12% SI 60.35% CRM 11.51% RIVN 0.32% ARKK 0.96% RLY.X 56.44% PLUG 6.72% V 0.22% CDIO 13.87% RETA 5.92% More Advertisement 3rd Party Ad. Do Not Sell My Personal Information (CA Residents Only). Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. Other than an emphasis on cell therapies, the companies had almost nothing in common. It's likely that the company will take longer to file for full FDA approval of the vaccine than Moderna will. Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. Nasdaq In this case, shares rallied about four-fold in just a few days. Investors were hopeful that the small drugmaker would be able to win U.S. CanSinoBio will receive some of the profits, but Ocugen still would skyrocket with FDA approval and ensuing revenue and there are more products in the pipeline. Outsmart the market with Smart Portfolio analytical tools powered by TipRanks. Ocugen Inc First Quarter 2022 Financial Results and Recent Business Highlights 04/21/2022 Noble Capital Markets' Eighteenth Annual Investor Conference 03/14/2022 34th Annual ROTH Conference 02/25/2022 Ocugen, Inc. Q4 and Full Year 2021 Financial Results and Recent Business Highlights 01/10/2022 H.C. Wainwright Bioconnect Conference 12/22/2021 It is focused on discovering, developing and commercializing therapies which address rare and underserved eye diseases. Keith Speights for From a near-term standpoint, there are two key risks. This can prove to be a costly lesson to learn. The stock had gained some traction after they announced the. The worst news was that another late-stage clinical study will likely be required to support the regulatory filing. Making the world smarter, happier, and richer. Thats why we give you a wide range of Options on stocks, indices, commodities and FX. Backlinks from other websites are the lifeblood of our site and a primary source of new traffic. Can you feel the ground moving beneath your feet? The newly renamed Ocugen stock kept declining through year-end, but has managed to stage a bit of a rally in 2020, gaining 15% year-to-date. Ocugen announced in late Decemberit had signed a letter of intent to co-develop COVID-19 vaccine candidate Covaxin along with Indian pharmaceutical company Bharat Biotech. The CanSinoBio partnership does help, but Ocugen still has a long way to go with OCU300. This requires no immediate effort on your part. The latest closing stock price for Ocugen as of March 03, 2023 is. After all, one cannot expect Ocugen stock to cure its ills when the company itself has fallen into critical condition. The Motley Fool->. The company has no revenue, runs an annual deficit, and does not generate positive free cash flow. Will Be Even Bigger Than Your Wildest Expectation, 7 Over-$100 Stocks That Are Worth Every Penny, Louis Navellier and the InvestorPlace Research Staff, 5 Penny Cryptos With the Most Potential for Growth. That's right -- they think these 10 stocks are even better buys. Even though Ocugen did raise $25 million in a private placement, the story behind OCU300 clearly was not enough to support an initial public offering on its own. Still, Ocugens balance sheet isnt as dire as its share price might suggest. The Ocugen 52-week high stock price is 4.03, which is 328.7% above the current share price. After encouraging preliminary results, Ocugen began trying to sell 100 million doses of the vaccine in February. Now, with the stock trading near the 40-cent per share level, its prospects have taken a dramatic turn for the worse. Theres even room for more lines. Like other life sciences companies involved in Covid-19 vaccine. Without NeoCart, that burn likely comes down. Sign up below to get this incredible offer! The company stated that it will pursue a path to file for full FDA approval of Covaxin. Investors need to understand the risk profile here. It peaked at a split-adjusted level of around $778 per share soon after its initial public offering in 2014. Like Pfizer's BNT162b2 and Moderna's mRNA-1273, it requires two doses. With no effective treatments, and without a clear reason to exist, I would avoid buying Ocugen stock even as a speculative play. However, I wont be around to find out. Bharat Biotech has a history of successful vaccine commercialization in South Asia. On June 10, though, Ocugen announced that the U.S. Food and Drug Administration (FDA) had effectively shut the door on an EUA filing. The huge gain came after the company's partner, Bharat Biotech, received emergency use authorization. For now, the biggest near-term hope for Covaxin may be that Canada or another developed economy will buy the vaccine to share with developing nations. To make the world smarter, happier, and richer. But any success they find will be without me as a shareholder. Hence, instead of ruining just two lives, this new Ocugen may be destroying the investment future of all who buy. Accordingly, the analyst rates OCGN a Neutral (i.e. You can be a growth investor, futures trader, deep-value investor, a day trader, options player, or a dividend aficionado. Thats one of the best rallies weve seen in that amount of time (95 trading sessions, 136 days). Realistically, Ocugen is probably looking at potential approval of Covaxin in mid-2023 at the earliest. At the beginning of 2020, Ocugen shares were trading at just 47 cents. Weitere Informationen ber die Verwendung Ihrer personenbezogenen Daten finden Sie in unserer Datenschutzerklrung und unserer Cookie-Richtlinie. It has real products. Emergency Use . The company does not earn revenue, relying on grants, a dwindling cash position, and stock dilution to keep its doors open. The FDA typically takes 60 days to accept a regulatory filing then 10 months to make an approval decision. The biotech stock promptly crashed by more than 30%. First, the balance sheet is in at least decent shape. In 2018, its NeoCart biologic failed to meet the primary endpoint of its own Phase III trial. A bout of buying in late July sent shares from 20 cents apiece to above 90 cents a share a few days. CEO Shankar Musunuri stated that he was "pleased to say" that Ocugen was in discussions with the FDA about the data it had submitted for the pediatric EUA. You'll now be able to see real-time price and activity for your symbols on the My Quotes of Nasdaq.com. Shares fell 72% on the news, and kept falling after Histogenics decided to suspend development of the product in December 2018. And a partnership with Chinas CanSino Biologics (OTCMKTS:CASBF) should help the company develop its pipeline. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. Start trading Options with Saxo today. But it does mean something. Custom BMW. These symbols will be available throughout the site during your session. OCGN Ocugen Inc 155,223 $0.9721 $0.0263 (2.63%) You could sell some or all of your Ocugen shares and buy long-term call options on the stock. Shares of Ocugen (NASDAQ: OCGN) were skyrocketing 64.2% higher as of 11:35 a.m. EST on Monday. The market capitalization of Relmada Therapeutics (NASDAQ:RLMD) went from under $10 million at the end of 2017 to over $500 million at the moment. David and Tom just revealed what they believe are the ten best stocks for investors to buy right now and Ocugen, Inc. wasn't one of them! The $25 million private placement executed before the merger brought in much-needed cash. 5 Hypergrowth Stocks With 10X Potential in 2023, Robert Bollinger: Meet the Man Behind Mullens Push Into Commercial EVs, A.I. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services. *Average returns of all recommendations since inception. Indeed, the price broke below the 24 December 2018 low at 4.81 and is currently attempting a return move. With No Revenue or Approved Treatments, Ocugen Stock Is a Clear Sell Amryt Pharma releases Q-2 how to setup copy trading labrador gold stock that show strong revenue growth as The first split for NKE took place on October 08, Below, we'll pit these two dominant consumer-discretionary giants against each other, with an eye toward long-term . Ocugen In 2021, Beyond: Optimism about Covaxin coupled with massive short squeezes in a handful of popular social media stocks sent Ocugen shares skyrocketing up to as high as $18.77 in February 2021. *Stock Advisor returns as of June 7, 2021. Type a symbol or company name. The company's product pipeline consists of OCU400, OCU300, OCU100 and OCU200 which are in clinical stage. (To watch Ramakanths track record, click here), In contrast, all 3 other analysts who have recently posted an Ocugen review rate the stock a Buy. When the symbol you want to add appears, add it to Watchlist by selecting it and pressing Enter/Return. The stock had gained some traction after they announced the Ocugen merger in April.
How Many Ww2 Bomber Crews Completed 25 Missions, Brisbane Music Festival 2022, Articles O